Parathyroid hormone helping bone cells use marrow fat
Official title: Parathyroid hormone (PTH) modulates lipid metabolism in the skeletal niche
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11466947 · Data updated 2026-11-12
This project looks at whether intermittent parathyroid hormone helps bone cells use fat in the marrow to build stronger bones for people with osteoporosis or low bone density.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 30, 2020 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $71,500 |
| NIH project number | 7R01AG069795-06 |
| Project ID | NIH-11466947 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with osteoporosis or osteopenia who are interested in new anabolic approaches to increase bone formation would be the most likely to benefit from advances stemming from this work.
✕Less likely to help
People without bone loss or those with bone diseases unrelated to PTH signaling or marrow lipid metabolism may not see direct benefit from this line of research.
What this research studies
As someone with low bone density, I'd hear that researchers are exploring how intermittent parathyroid hormone (the kind already used to boost bone formation) changes fat inside the bone marrow and how bone cells use that fat. They are testing two linked ideas: that the hormone makes marrow fat cells release lipid molecules, and that bone-building osteoblasts increase their use of those lipids for energy. The team uses lab-based molecular experiments, cell models, and likely animal models to trace lipid release and uptake within the skeletal niche. The aim is to map these steps so future therapies can better support the energy needs of bone formation.
Why it matters
Potential benefit: If successful, this work could point to ways to boost bone formation with fewer side effects by targeting how bone cells use lipids in the marrow.
How similar studies have gone: Intermittent PTH (for example, teriparatide) is already known to increase bone formation clinically, but connecting PTH's benefits to marrow lipid metabolism is a newer and less-tested concept.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Rendina-Ruedy, Elizabeth — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rendina-Ruedy, Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Primary care research network in Oklahoma to boost rural patient trials
A nationwide NIH-supported effort to strengthen Oklahoma’s primary care research network so doctors can run big clinical trials and real‑world studies in rural communities.
-
N-myristoylation and DNA damage response in Alzheimer’s disease
A study to understand how a protein modification called myristoylation affects the DNA damage response in people who have Alzheimer’s-related conditions.
-
Genetically engineered mouse model to study and treat high-risk pediatric rhabdomyosarcoma
A research project aims to create mouse models that mimic high-risk pediatric rhabdomyosarcoma and test therapies that target the NOTCH1 pathway to slow or stop tumor growth.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
TFEB as a key switch to keep muscles healthy as we age
A study in aging adults and aging muscle tissues looks at whether boosting TFEB can improve how muscles maintain themselves and recover after disuse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.